As legislators consider policy and regulatory options to lower the cost of prescription drugs, the American College of Rheumatology (ACR) is calling for an end to step therapy (or sometimes called “fail first” policies) as well as the switching of medications in stable patients purely for cost reasons.
As legislators consider policy and regulatory options to lower the cost of prescription drugs, the American College of Rheumatology (ACR) is calling for an end to step therapy (or sometimes called “fail first” policies) as well as the switching of medications in stable patients purely for cost reasons.
Non-medical switching in a stable patient among branded products and across therapeutic classes without the consent of the patient and the provider is inappropriate and potentially harmful, the ACR says.
“We continue to emphasize these topics because they are so critical to the well-being of millions of Americans living with rheumatic diseases, some of which can be quite debilitating and even lead to death,” says Colin Edgerton, MD, a rheumatologist at Low Country Rheumatology in South Carolina and chair of the ACR’s Committee on Rheumatologic Care, in a statement. “The need for patients to have access to prompt, affordable, and medically necessary treatments is ongoing and should be considered at every step of the policy making process.”
The statement comes as several bills regarding prescription prices, as well as making biosimilars more accessible, have been introduced in Congress.
One of these bills, the Medicare Negotiation and Competitive Licensing Act, would allow the HHS secretary to negotiate prices for Medicare Part D drugs directly. Another, while not directly targeting prices, aims at unraveling the patent thickets that prevent biosimilars from coming to market.
On the regulatory side, CMS is allowing the use of step therapy in Medicare Advantage plans.
The ACR’s position statement on drug pricing asks for:
ACR’s step therapy statement asks that pharmacy review committees include rheumatologists to help develop formulary benefits programs.
“Step therapy has resulted in forced drug switching, treatment gaps, and cessation of effective therapy,” the statement says. “In addition to the dangers to the patient related to loss of access to therapy and disease flares, these programs may result in immunogenicity, adverse effects, and secondary nonresponse. Downstream effects of restricted access can lead to complications such as uncontrolled disease for the patient, disabilities, and increased health care costs.”
Last year, the ACR released its first-ever Rheumatic Disease Report Card, which shows the burden of rheumatic disease in each state. The average state grade was a “C.”
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.